-
公开(公告)号：US20220058408A1
公开(公告)日：2022-02-24
申请号：US17593234
申请日：2020-03-10
摘要： Aspects of the present disclosure relate to a control system, system and method for controlling a transition between a first driving mode and a second driving mode of a vehicle. The present disclosure relates to receiving image data of an occupant of the vehicle; quantifying one or more characteristics of the occupant's gaze based at least in part on the received image data, the one or more characteristics being indicative of the occupant's attention to a non-driving task; determining a transition profile for transitioning between the first driving mode and the second driving mode based at least in part on the one or more characteristics of the occupant's gaze; and generating and outputting a control signal to transition from the first driving mode to the second driving mode, the control signal comprising instructions for controlling one or more vehicle systems in accordance with the determined transition profile.
-
公开(公告)号：US11236261B2
公开(公告)日：2022-02-01
申请号：US16549399
申请日：2019-08-23
发明人： Philippe Prince , Loan Vo , Deepak S. Monteiro , Tai Duc Bui , Alberto Striolo
摘要： Methods involving anti-agglomerant hydrate inhibitors and polyaromatic hydrocarbons for hydrate inhibition are provided. In some embodiments, the methods include introducing a hydrate inhibitor composition including an anti-agglomerant hydrate inhibitor into a fluid including (i) water and (ii) one of gas, liquid hydrocarbon, and any combination thereof; and introducing a polyaromatic hydrocarbon into the fluid.
-
公开(公告)号：US11109962B2
公开(公告)日：2021-09-07
申请号：US16317347
申请日：2017-07-13
申请人： UCL Business PLC
摘要： Bioprosthetic heart valves and methods for fabricating bioprosthetic heart valves are provided. Biological tissue is attached to biocompatible material. The biocompatible material is folded to form a tubular structure with the attached biological tissue located on the inner surface of the tubular structure, the biological tissue forming leaflets of the heart valve. A stent is secured around the outer surface of the tubular structure. A region of the biocompatible material is cut. The biocompatible material is folded at the cut region away from the tissue and around the downstream edge of the stent and is secured to the stent's outer surface. The biocompatible material is folded at the upstream end of the tubular structure around the upstream edge of the stent and attached to the stent's outer surface so that the stent's inner and outer surfaces are covered with no more than a single layer of the biocompatible material.
-
公开(公告)号：US11033897B2
公开(公告)日：2021-06-15
申请号：US14705309
申请日：2015-05-06
申请人： UCL BUSINESS PLC
发明人： Nicolas Szita , Marcel Reichen
摘要： The invention relates to a microfluidic device including a chamber having a fluid inlet, a fluid outlet and a sealable port. In some embodiments, the fluid inlet and the fluid outlet may be positioned to direct fluid flowing from the fluid inlet to the fluid outlet through the chamber. Various embodiments may include a sealable port which may be aligned with the chamber to allow material to be placed directly into, or removed from, the chamber from the exterior of the device when the sealable port is open, and to inhibit and/or prevent fluid escaping through the sealable port when the port is sealed.
-
公开(公告)号：US20210093867A1
公开(公告)日：2021-04-01
申请号：US15733274
申请日：2018-12-11
摘要： A nerve stimulation system is disclosed including a nerve interface device having a cuff that receives a nerve of a user; and first and second rings of electrodes mounted on the cuff, each ring of electrodes including a plurality of electrodes and wherein each electrode in the first ring has a corresponding longitudinally-aligned electrode in the second ring so as to form a plurality of pairs of electrodes spaced apart from each other along the longitudinal axis. The system includes a stimulation device in communication with the pairs of electrodes to generate different electrical signals for the pairs of electrodes, a signal routing module to store signal routing information necessary to cause a physiological response in a user and to cause the signals to be delivered accordingly, and a configuration module for monitoring and updating the signal routing information based on information detected or received by the nerve stimulation system.
-
公开(公告)号：US10963741B2
公开(公告)日：2021-03-30
申请号：US16307813
申请日：2016-06-07
发明人： Jonas Ambeck-Madsen , Ichiro Sakata , Nilli Lavie , Gabriel J. Brostow , Luke Palmer , Alina Bialkowski
摘要： The invention relates to a control device (1) for a vehicle for determining the perceptual load of a visual and dynamic driving scene. The control device is configured to: receive a sensor output (101) of a sensor (3), the sensor (3) sensing the visual driving scene, extract a set of scene features (102) from the sensor output (101), the set of scene features (102) representing static and/or dynamic information of the visual driving scene, and determine the perceptual load (104) of the set of extracted scene features (102) based on a predetermined load model (103), wherein the load model (103) is predetermined based on reference video scenes each being labelled with a load value The invention further relates to a system and a method.
-
公开(公告)号：US10426845B2
公开(公告)日：2019-10-01
申请号：US15764742
申请日：2016-09-30
申请人： UCL Business PLC
发明人： Amit Nathwani , Maria Notaridou
摘要： There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional preproinsulin protein wherein the nucleotide sequence has at least 86% identity to the sequence of SEQ ID NO. 1. Also described are: vectors comprising the nucleic acid molecule for expressing the preproinsulin protein; host cells comprising the nucleic acid molecule or a vector; a transgenic animal comprising cells comprising the nucleic acid molecule or the vector; a pharmaceutical composition comprising the nucleic acid molecule or the vector; a method of treating diabetes comprising administering a therapeutically effective amount of the vector to a patient suffering from diabetes; the nucleic acid molecule for use in therapy; and the nucleic acid molecule or the vector for use in the treatment of diabetes.
-
公开(公告)号：US10414803B2
公开(公告)日：2019-09-17
申请号：US15573350
申请日：2016-05-10
申请人： UCL Business PLC
发明人： Amit Nathwani , Allison Dane
IPC分类号： C12N15/00 , C07K14/005 , C12N15/86 , A61K48/00
摘要： There is described an AAV capsid protein having an amino acid sequence which has at least 98% identity to the sequence of SEQ ID NO: 3 or at least 94% identity to the sequence of SEQ ID NO: 4. Also described is a pharmaceutical composition, an AAV capsid and a viral particle comprising the capsid protein, a recombinant AAV vector comprising a nucleotide sequence which encodes for the capsid protein, and a host cell and a transgenic animal comprising the capsid protein or the vector. In addition, there is described a method of transferring a nucleic acid of interest into a mammal comprising introducing a recombinant AAV vector into the mammal, wherein the recombinant AAV vector comprises a gene of interest which is encapsidated into a capsid comprising the capsid protein.
-
公开(公告)号：US10376518B2
公开(公告)日：2019-08-13
申请号：US14780104
申请日：2014-03-28
申请人： UCL Business PLC
发明人： Shawn Ellis , Clare Notley , Michael Ehrenstein
IPC分类号： A61K39/395 , A61K31/5377 , A61K45/06 , A61K31/4155 , C07K16/28 , G01N33/564 , G01N33/68
摘要： The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.
-
公开(公告)号：US10118892B2
公开(公告)日：2018-11-06
申请号：US14435046
申请日：2013-10-14
申请人： UCL BUSINESS PLC
发明人： Erik Arstad , Kerstin Sander , Thibault Gendron
IPC分类号： C07C381/12 , C07C17/361 , C07C25/13 , C07C45/65 , C07C47/55 , C07C49/807 , C07C67/317 , C07C69/78 , C07D207/46 , C07D211/20 , C07D211/22 , C07D211/32 , C07D211/70 , C07D213/70 , C07D333/74 , C07D333/76 , C07D401/06 , C07D403/06 , B01D15/08 , B01J20/22 , C07B59/00 , C07D213/61
摘要： The present invention relates to sulfonium salts of formula (I): (I), their preparation, and utility as precursors for preparing functionalized organic compounds, wherein R1 and R2 are the same or different and each is independently selected from an optionally substituted aryl group, an optionally substituted alkynyl group, an optionally substituted alkenyl group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aralkyl group, an optionally substituted arylalkenyl group, an optionally substituted heteroaryl group, an optionally substituted heterocyclyl group, an optionally substituted amine, an optionally substituted alkoxy group, an optionally substituted thioether group, an optionally substituted phosphine group, an optionally substituted boron species, an optionally substituted carbene, an organometallic moiety, and a halide, or R1 and R2 are joined together to form an optionally substituted sulfur-containing ring; W is a bond, an optionally substituted alkynylene group, an optionally substituted alkenylene group, and optionally substituted alkylene group, an optionally substituted heterocyclyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group; R3 is a moiety comprising at least one basic group, provided that when R3 does not contain any carbon atoms, W is not a bond; X is an anionic species; and n is an integer selected from 1 to 5.
-
-
-
-
-
-
-
-
-
搜索结果
321 条记录 (耗时 0.033 秒)
